PRGN-2009 plus Pembrolizumab + Pembrolizumab alone
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Trial Timeline
Mar 21, 2025 → Jan 30, 2028
NCT ID
NCT06157151About PRGN-2009 plus Pembrolizumab + Pembrolizumab alone
PRGN-2009 plus Pembrolizumab + Pembrolizumab alone is a phase 2 stage product being developed by Precigen for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06157151. Target conditions include Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06157151 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cervical Cancer